![]() |
市場調查報告書
商品編碼
2087873
外科黏合劑市場:2026-2032年全球市場預測(按產品類型、配方、應用、最終用戶和分銷管道分類)Surgical Glue Market by Product Type, Formulation, Application, End User, Distribution Channel - Global Forecast 2026-2032 |
||||||
※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。
預計到 2032 年,外科黏合劑市場將成長至 36.9 億美元,複合年成長率為 6.05%。
| 主要市場統計數據 | |
|---|---|
| 基準年 2025 | 24.4億美元 |
| 預計年份:2026年 | 25.9億美元 |
| 預測年份:2032年 | 36.9億美元 |
| 複合年成長率 (%) | 6.05% |
外科黏合劑,也稱為組織黏合劑、外科密封劑或外科黏合劑,在心血管外科、一般外科、整形外科、神經外科、婦科、創傷外科、整形外科和微創手術中得到越來越廣泛的應用,用於輔助傷口縫合、止血、組織密封和防止滲漏。此類別包括氰基丙烯酸酯黏合劑、纖維蛋白膠、聚乙二醇水凝膠、白蛋白-戊二醛製劑、明膠-凝血酶基質、膠原蛋白產品以及其他黏合劑製劑,旨在減少臨床適用情況下對縫線、縫合釘和機械固定的依賴。
外科黏合劑市場正從基本的傷口縫合轉向臨床專用黏合劑平台,這些平台旨在匹配目標組織類型、性能特徵和手術流程。醫院在評估黏合劑時,不僅考慮採購成本,還越來越注重手術的整體價值,包括手術室使用時間、術後併發症風險、住院時間、避免再次入院以及與腹腔鏡、機器人手術和內視鏡給藥系統的兼容性。
人工智慧 (AI) 正透過材料發現、生產管理、臨床決策支援、品質保證和需求預測等手段,逐步影響外科黏合劑的價值鏈。在研發階段,AI 驅動的建模能夠在高成本的實驗室檢驗之前,對聚合物結構、分解特性、黏度範圍、固化行為、機械強度和組織相互作用特性進行篩檢。這使得研發團隊能夠在滿足生物相容性、毒性和滅菌穩定性要求的前提下,快速縮小候選配方範圍。
亞太地區為外科黏合劑市場提供了巨大的機遇,這主要得益於中國、印度、日本、韓國、澳洲和東協等國家外科手術能力的不斷提升,以及醫療旅遊、醫療保健支出的成長和微創手術的日益普及。儘管當地價格敏感度仍然是一個關鍵因素,但在三級醫療機構中,由於外科醫生優先考慮止血、控制滲漏、快速縫合以及在複雜手術中可靠的性能,高價產品的使用率正在不斷提高。
在東協地區,新加坡、泰國、馬來西亞、印尼、越南和菲律賓等國對醫院的投資不斷增加,醫療旅遊蓬勃發展,擇期手術和專科手術也日益增多,這些都推動了外科黏合劑的使用。外科黏合劑的使用模式多種多樣,高階組織黏合劑和外科密封劑主要集中在三級醫療機構,而經濟實惠的配方則因其在公立和私立醫院各種外科手術中的應用而備受關注。
美國在外科黏合劑的商業化方面處於領先地位,這得益於其龐大的手術量、專家們的積極採用、完善的醫院採購體係以及重視臨床檢驗技術的法律規範。在加拿大,醫院系統注重安全性、採購規範、成本效益和循證產品選擇,因此對外科黏合劑的需求穩定。墨西哥和巴西是拉丁美洲的主要市場,當地的私立醫院、都市區專科醫療中心以及不斷擴大的手術能力,都促進了先進傷口縫合和止血產品的早期應用。
產業領導者應優先考慮能夠證明其可衡量價值的程序性證據,例如縮短縫合時間、預防滲漏、提高止血效果、降低併發症率、減少再次手術以及與微創手術技術的兼容性。臨床聲明必須與已批准的適應症一致,並有設計良好的研究、註冊研究、可用性評估或真實世界數據支持。
本執行摘要的調查方法整合了二手資料研究、監管審查、臨床證據評估和市場三角驗證。所考慮的資訊來源包括公共法規結構、醫院採購趨勢、同行評審的外科文獻、臨床實踐模式、產品類型資訊披露、不利事件監測原則以及宏觀層面的醫療保健指標,例如手術能力、人口老化、慢性病負擔和微創手術的普及率。
外科黏合劑市場正從輔助傷口縫合手段發展成為涵蓋止血、密封、組織修復和微創手術支援的策略性外科技術類別。推動這一成長的因素包括手術數量的增加、微創手術的普及、人口老化、慢性病患病率上升以及醫院對高效、循證解決方案的需求。
The Surgical Glue Market is projected to grow by USD 3.69 billion at a CAGR of 6.05% by 2032.
| KEY MARKET STATISTICS | |
|---|---|
| Base Year [2025] | USD 2.44 billion |
| Estimated Year [2026] | USD 2.59 billion |
| Forecast Year [2032] | USD 3.69 billion |
| CAGR (%) | 6.05% |
Surgical glue, also known as tissue adhesive, surgical sealant, or surgical adhesive, is increasingly used to support wound closure, hemostasis, tissue sealing, and leakage prevention across cardiovascular, general, orthopedic, neurosurgical, gynecological, trauma, plastic, and minimally invasive procedures. The category includes cyanoacrylate adhesives, fibrin sealants, polyethylene glycol-based hydrogels, albumin-glutaraldehyde systems, gelatin-thrombin matrices, collagen-based products, and other bioadhesive formulations designed to reduce reliance on sutures, staples, and mechanical fixation where clinically appropriate.
Demand is supported by verified healthcare trends, including rising surgical procedure volumes, aging populations, higher prevalence of chronic diseases requiring operative intervention, and the shift toward shorter hospital stays and faster recovery pathways. Surgical glue is valued because it can improve procedural efficiency, reduce needle-stick exposure, limit tissue trauma, and support closure in anatomically challenging or fragile tissue environments. Adoption, however, remains shaped by product-specific clinical evidence, surgeon preference, reimbursement pathways, sterility assurance, storage requirements, applicator usability, and regulatory classification, particularly where adhesives contact blood, dura, lung, gastrointestinal tissue, or vascular structures.
The surgical glue landscape is shifting from basic wound closure toward clinically specialized adhesive platforms designed for targeted tissue types, performance profiles, and surgical workflows. Hospitals are increasingly evaluating adhesives not only on acquisition cost, but also on total procedural value, including operating room time, post-operative complication risk, length of stay, readmission avoidance, and compatibility with laparoscopic, robotic, and endoscopic delivery systems.
Regulatory scrutiny is also transforming competition. In the United States, surgical adhesives may be regulated as medical devices, biologics, or combination products depending on composition and intended use, while the European Union Medical Device Regulation has increased clinical evidence, technical documentation, and post-market surveillance expectations. These requirements are encouraging manufacturers to invest in robust clinical data, biocompatibility testing, validated sterilization, risk management, usability engineering, and clearer product differentiation.
Innovation is moving toward bioresorbable, flexible, low-toxicity, fast-setting, and wet-field adhesive technologies. Demand is strongest where adhesives solve persistent surgical challenges, such as air leaks after lung surgery, cerebrospinal fluid leaks, vascular bleeding, skin closure, and sealing of friable tissues. As procurement teams pursue standardization, suppliers with broad portfolios, application training, reliable supply chains, and documented outcomes are gaining strategic relevance.
Artificial intelligence is beginning to influence the surgical glue value chain through materials discovery, manufacturing control, clinical decision support, quality assurance, and demand planning. In research and development, AI-enabled modeling can screen polymer structures, degradation profiles, viscosity ranges, curing behavior, mechanical strength, and tissue interaction characteristics before expensive laboratory validation, helping teams narrow formulation candidates faster while maintaining requirements for biocompatibility, toxicology, and sterilization stability.
In manufacturing and quality assurance, machine vision, predictive maintenance, and AI-supported statistical process controls can help identify batch variability, packaging defects, fill-volume inconsistencies, applicator issues, and sterility-risk signals earlier. This is relevant for surgical glue because adhesive performance is highly dependent on formulation consistency, delivery mechanism, storage conditions, temperature sensitivity, and shelf-life integrity.
In clinical and commercial settings, AI can support evidence generation by analyzing real-world data, surgical outcomes, adverse event patterns, and complication signals across procedure types. While AI does not replace surgeon judgment, clinical trials, or regulatory evidence, it can strengthen post-market surveillance, optimize inventory by procedure mix, improve training targeting, and help manufacturers align product education with high-need specialties.
Asia-Pacific is a high-opportunity region for surgical glue due to expanding surgical capacity, medical tourism, rising healthcare expenditure, and growing adoption of minimally invasive procedures in China, India, Japan, South Korea, Australia, and ASEAN economies. Local price sensitivity remains important, but premium adoption is increasing in tertiary hospitals where surgeons prioritize hemostasis, leakage control, faster closure, and reliable performance in complex procedures.
North America remains one of the most mature regions, supported by advanced surgical infrastructure, high procedure volumes, strong reimbursement systems for many operative interventions, and rapid uptake of evidence-backed medical devices. The United States is particularly influential in clinical validation, regulatory benchmarking, and product commercialization, while Canada emphasizes health technology assessment, cost-effectiveness, safety, and procurement discipline across publicly funded hospital systems.
Europe is shaped by established hospital systems, specialized surgical centers, and stricter evidence requirements under the European Union Medical Device Regulation. Germany, France, Italy, Spain, and the United Kingdom continue to create demand for advanced sealants in cardiovascular, thoracic, neurosurgical, gastrointestinal, and general surgery applications. Latin America, led by Brazil and Mexico, is expanding gradually as private hospital networks adopt advanced wound closure, hemostatic, and tissue sealing technologies. The Middle East, especially GCC markets, is investing in specialty care, trauma centers, and high-acuity hospitals, while Africa presents longer-term demand tied to surgical access expansion, emergency care, trauma management, and public-private healthcare investment.
Within ASEAN, surgical glue adoption is supported by rising hospital investment, medical tourism, and growth in elective and specialty surgeries across Singapore, Thailand, Malaysia, Indonesia, Vietnam, and the Philippines. Adoption patterns vary widely, with premium tissue adhesives and surgical sealants concentrated in tertiary centers, while cost-effective formulations are gaining attention for broader surgical use in public and private hospitals.
The GCC is becoming a strategic market because of government-backed healthcare modernization, high-income patient populations, and investments in cardiovascular, trauma, oncology, transplant, and advanced surgical services. Hospitals in Saudi Arabia, the United Arab Emirates, Qatar, Kuwait, Bahrain, and Oman often prioritize internationally approved technologies with strong clinical evidence, reliable supplier support, and structured clinician training.
The European Union is highly regulated and evidence-driven, making CE marking under the EU MDR, clinical evaluation, technical documentation, and post-market performance central to access. BRICS economies combine large procedure volumes with diverse reimbursement and procurement environments, creating opportunities for tiered pricing, localized distribution, and domestic manufacturing partnerships. G7 countries remain innovation leaders due to strong academic medicine, established surgical societies, advanced regulatory systems, and high clinical evidence expectations, while NATO member countries add demand through trauma readiness, defense medical capabilities, emergency surgical preparedness, and resilient medical supply planning.
The United States leads surgical glue commercialization through high surgical volumes, strong specialist adoption, sophisticated hospital purchasing, and a regulatory framework that rewards clinically validated technologies. Canada offers steady demand through hospital systems that emphasize safety, procurement discipline, cost-effectiveness, and evidence-based product selection. Mexico and Brazil are key Latin American markets where private hospitals, urban specialty centers, and expanding surgical capacity support early adoption of advanced wound closure and hemostatic products.
In Europe, the United Kingdom supports demand through advanced surgical practice and health economic scrutiny, while Germany's high procedural intensity, specialized hospitals, and medical device ecosystem make it a core market for surgical adhesives and sealants. France, Italy, and Spain show sustained use in hospital-based surgical care, though procurement pressure, reimbursement rules, and regional purchasing structures shape adoption. Russia remains a sizable but complex market influenced by import dynamics, localization priorities, regulatory requirements, and healthcare investment variability.
China is expanding rapidly due to healthcare infrastructure growth, domestic device innovation, and increasing access to advanced surgical procedures. India presents significant long-term opportunity as procedure volumes rise and private hospitals adopt advanced closure technologies, although affordability and reimbursement remain decisive. Japan values premium, evidence-backed products and precision surgical practice, while Australia and South Korea show strong demand in specialized hospitals with high standards for safety, training, infection control, and clinical performance.
Industry leaders should prioritize procedure-specific evidence that demonstrates measurable value, including reduced closure time, leakage prevention, hemostatic performance, lower complication rates, fewer reinterventions, and compatibility with minimally invasive techniques. Clinical claims must be aligned with approved indications and supported by well-designed studies, registries, usability assessments, or real-world evidence.
Manufacturers should segment portfolios by tissue type, specialty, risk profile, and healthcare setting rather than relying on a single universal adhesive message. Training programs for surgeons, nurses, and operating room staff are essential because application technique, surface preparation, field moisture, temperature, and curing conditions directly affect outcomes.
Commercial teams should strengthen regional market access strategies, including EU MDR readiness, FDA pathway planning, local distributor qualification, reimbursement mapping, tender preparation, and procurement-focused value dossiers. Strategic partnerships with hospitals, academic centers, simulation programs, and robotic or endoscopic device ecosystems can accelerate adoption in high-growth surgical segments.
The research methodology for this executive summary integrates secondary research, regulatory review, clinical evidence assessment, and market triangulation. Sources considered include public regulatory frameworks, hospital procurement trends, peer-reviewed surgical literature, clinical practice patterns, product category disclosures, adverse event monitoring principles, and macro healthcare indicators such as surgical capacity, demographic aging, chronic disease burden, and minimally invasive surgery adoption.
Insights are validated by comparing product category behavior across regions, procedure types, material classes, and regulatory classifications. The analysis emphasizes verified drivers and constraints rather than unsupported market-size, market-share, or forecasting claims. Particular attention is given to clinical utility, material science differentiation, safety expectations, reimbursement sensitivity, usability, sterilization, shelf-life requirements, and post-market evidence obligations that influence surgical glue adoption.
The surgical glue market is evolving from a wound closure adjunct into a strategic surgical technology category spanning hemostasis, sealing, tissue repair, and minimally invasive procedure support. Growth is supported by rising procedure volumes, minimally invasive surgery, aging demographics, chronic disease prevalence, and hospital demand for efficient, evidence-backed solutions.
Competitive advantage will depend on clinical proof, regulatory execution, material innovation, application training, supply reliability, and the ability to demonstrate total procedural value. Organizations that align advanced adhesive science with surgeon needs, payer expectations, procurement requirements, and regional market access standards will be best positioned for durable relevance in surgical care.